Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response

Furrie E; Macfarlane S; Cummings J H; Macfarlane G T
January 2004
Gut;Jan2004, Vol. 53 Issue 1, p91
Academic Journal
BACKGROUND AND AIMS: The mucosa in ulcerative colitis (UC) is replete with antibody producing plasma B cells and polymorphonuclear leucocytes (PMN). This combination of effector cells requires a crosslinking antigen to evoke an antibody driven PMN inflammatory response via their Fc receptors. The stimulus for activation is thought to be commensal bacteria colonising the gut mucosa. The aim of this investigation was to compare the principal culturable bacterial populations on the rectal mucosa of UC patients, and to determine whether specific antibodies towards these bacteria can activate infiltrating PMN through opsonisation. This would provide an explanation for this chronic inflammatory condition. METHODS: Bacteria colonising rectal tissue were characterised using chemotaxonomic techniques. Systemic antibody responses were measured against total antigens and surface antigens of these organisms in UC and Crohn's disease (CD) patients, together with healthy controls. Antibody enhancement of the respiratory burst in PMN was also investigated, against a range of mucosal isolates. RESULTS: Distinct differences were observed in some bacterial populations in UC biopsies, which were generally reflected in antibody responses towards these organisms. UC patients had higher IgG responses to surface antigens, primarily IgG1, whereas the response in CD was mainly IgG2. Antibodies from UC patients greatly enhanced the respiratory burst in PMN, in response to individual bacterial species. CONCLUSIONS: Changes in mucosal bacteria, and a switch from internal to surface antigen/antibody reactivity of a predominantly IgG1 type, leads to greater opsonisation of the respiratory burst in PMN, providing a mechanism for maintaining the inflammatory state in UC.


Related Articles

  • Evaluation of Antibody Response to Polysaccharide Vaccine and Switched Memory B Cells in Pediatric Patients with Inflammatory Bowel Disease. Gholamhossein Fallahi; Asghar Aghamohammadi; Ahmad Khodadad; Mojtaba Hashemi; Payam Mohammadinejad; Hossein Asgarian-Omran; Mehri Najafi; Fatemeh Farhmand; Farzaneh Motamed; Khadije Soleimani; Habib Soheili; Nima Parvaneh; Behzad Darabi; Rasoul Nasiri Kalmarzi; Shabnam Pourhamdi; Hassan Abolhassani; Babak Mirminachi; Nima Rezaei // Gut & Liver;Jan2014, Vol. 8 Issue 1, p24 

    Background/Aims: Inflammatory bowel disease (IBD) is a chronic disease of the gastrointestinal tract, whose etiologies are still unknown. This study was performed to evaluate the humoral immune response in terms of B cell functions in selected IBD patients. Methods: Eighteen pediatric patients...

  • Current Therapeutic Approaches in Inflammatory Bowel Disease. Sohrabpour, Amir Ali; Malekzadeh, Reza; Keshavarzian, Ali // Current Pharmaceutical Design;11/28/2010, Vol. 16 Issue 33, p3668 

    No abstract available.

  • Evolving paradigms in the pathogenesis of IBD. Mayer, Lloyd // Journal of Gastroenterology;Jan2010, Vol. 45 Issue 1, p9 

    The pathogenesis of all immune-mediated inflammatory diseases has been carefully studied over the past several decades, but it is only recently that we have come to appreciate common pathways and genes. This is especially true for the inflammatory bowel diseases (IBD) Crohn’s disease and...

  • Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Sandborn, W. J.; Loftus, E. V. // Gut;Jun2004, Vol. 53 Issue 6, p780 

    Infliximab, a monoclonal antibody to tumor necrosis factor α, is an important advance in the treatment of Crohn's disease. The efficacy of infliximab for the treatment of ulcerative colitis is still unclear. All patients in the study initially received at least one induction dose of...

  • Research drug shows promise in IBD.  // New Zealand Doctor;9/11/2013, p42 

    The article presents a research study, funded by Takeda Pharmaceuticals, suggests that an investigational antibody named vedolizumab has potential as a new treatment alternative for Crohn's disease (CD), ulcerative colitis and inflammatory bowel diseases.

  • Detection of Antisynthetic Mannoside Antibodies (AΣMA) Reveals Heterogeneity in the ASCA Response of Crohn's Disease Patients and Contributes to Differential Diagnosis, Stratification, and Prediction. Khoury, Peggy Vandewalle-El; Colombel, Jean-Frederic; Joossens, Sofie; Standaert-Vitse, Annie; Collot, Mayeul; Halfvarson, Jonas; Ayadi, Ali; Landers, Carol J.; Vermeire, Severine; Rutgeerts, Paul; Targan, Stephan R.; Chamaillard, Mathias; Mallet, Jean-Maurice; Sendid, Boualem; Poulain, Daniel // American Journal of Gastroenterology;Apr2008, Vol. 103 Issue 4, p949 

    OBJECTIVES: Anti- S. cerevisiae mannan antibodies (ASCA) are human antibodies associated with Crohn's disease (CD) reacting with Saccharomyces cerevisiae ( S. cerevisiae) mannan polymer. As mannan is a complex and variable repertoire of oligomannoses acting as epitopes, we chemically synthesized...

  • Novel Anti-Glycan Antibodies Related to Inflammatory Bowel Disease Diagnosis and Phenotype. Seow, Cynthia H.; Stempak, Joanne M.; Wei Xu; Hui Lan; Griffiths, Anne M.; Greenberg, Gordon R.; Steinhart, A. Hillary; Dotan, Nir; Silverberg, Mark S. // American Journal of Gastroenterology;Jun2009, Vol. 104 Issue 6, p1426 

    OBJECTIVES:We sought to evaluate whether two novel immunoglobulin A (IgA) cell wall polysaccharide antibodies, anti-laminarin (anti-L) and anti-chitin (anti-C), aid in the diagnosis and phenotype differentiation of Crohn's disease (CD) and ulcerative colitis (UC).METHODS:A cohort of 818...

  • Increased IgA Glycoprotein-2 Specific Antibody Titres in Refractory Celiac Disease. Gross, Sascha; Bakker, Sjoerd F.; van Bodegraven, Adriaan A.; van Hoogstraten, Ingrid M. W.; Gelderman, Kyra A.; Bouma, Gerd; Mulder, Chris J.; von Blomberg, B. Mary E.; Bontkes, Hetty J. // Journal of Gastrointestinal & Liver Diseases;Jun2014, Vol. 23 Issue 2, p127 

    Background & Aims: In most cases celiac disease (CD) is successfully treated with a gluten-free diet (GFD). However, some patients become refractory to the GFD. Refractory CD (RCD) patients have an increased risk for developing enteropathy associated T-cell lymphoma and early diagnosis is...

  • ASCA -- New Marker for Crohn's Disease!? Young, R. L.; Thompson, Jon S. // American Journal of Gastroenterology;Nov1998, Vol. 93 Issue 11, p2020 

    Discusses research being done on anti-Saccharomyces cerevisiae mannan antibodies as a marker for Crohn's disease. Reference to a study by J.F. Quinton et al; Means to help delineate ulcerative colitis from Crohn's disease; Findings of serum samples from patients with Crohn's disease, ulcerative...


Read the Article


Sign out of this library

Other Topics